NEW YORK — Immunodiagnostics firm Avioq recently announced that it has received CE marking for its VioOne HIV Profile supplemental assay and has begun marketing the test in the European Union and other geographies that recognize the designation.
VioOne HIV supplemental assay is an ELISA test and is used to confirm and differentiate individual antibodies directed to various gene products of HIV-1 (group M and group O) and HIV-2 in human serum or plasma that were repeatedly reactive in diagnostic screening procedures, Research Triangle Park, North Carolina-based Avioq said. It added that results from the test can be used to distinguish recent HIV-1 infection from longstanding infection for HIV-1 incidence estimation.
Avioq has submitted the test for approval from the US Food and Drug Administration.